[ CAS No. 502649-29-8 ] {[proInfo.proName]}

Name: 502649-29-8|1-Boc-3-Benzylpiperazine|97%
Brand: Ambeed
SKU: A124543
Price: 23.0 USD
Availability: InStock
Rating: 99 (29 reviews)

,{[proInfo.pro_purity]}

Cat. No.: {[proInfo.prAm]}

2D 3D

Structure of 502649-29-8 * Storage: {[proInfo.prStorage]}

Cart0 Add to My Favorites Add to My Favorites Bulk Inquiry Inquiry Add To Cart

Search after Editing

* Storage: {[proInfo.prStorage]}

For Research Only 110K+ Compounds Competitive Price 1-2 Day Shipping

Quality Control of [ 502649-29-8 ]

COA NMR CNMR HPLC LC-MS

Related Doc. of [ 502649-29-8 ]

SDS Specification

Alternatived Products of [ 502649-29-8 ]

Product Details of [ 502649-29-8 ]

CAS No. :	502649-29-8	MDL No. :	MFCD07367736
Formula :	C₁₆H₂₄N₂O₂	Boiling Point :	-
Linear Structure Formula :	-	InChI Key :	YFIAVMMGSRDLLG-UHFFFAOYSA-N
M.W :	276.37	Pubchem ID :	44118664
Synonyms :

Calculated chemistry of [ 502649-29-8 ]

Physicochemical Properties

Num. heavy atoms :	20
Num. arom. heavy atoms :	6
Fraction Csp3 :	0.56
Num. rotatable bonds :	5
Num. H-bond acceptors :	3.0
Num. H-bond donors :	1.0
Molar Refractivity :	87.8
TPSA :	41.57 Å²

Pharmacokinetics

GI absorption :	High
BBB permeant :	Yes
P-gp substrate :	No
CYP1A2 inhibitor :	No
CYP2C19 inhibitor :	No
CYP2C9 inhibitor :	No
CYP2D6 inhibitor :	Yes
CYP3A4 inhibitor :	No
Log Kp (skin permeation) :	-6.23 cm/s

Lipophilicity

Log Po/w (iLOGP) :	3.16
Log Po/w (XLOGP3) :	2.48
Log Po/w (WLOGP) :	1.68
Log Po/w (MLOGP) :	2.18
Log Po/w (SILICOS-IT) :	2.21
Consensus Log Po/w :	2.34

Druglikeness

Lipinski :	0.0
Ghose :	None
Veber :	0.0
Egan :	0.0
Muegge :	0.0
Bioavailability Score :	0.55

Water Solubility

Log S (ESOL) :	-3.01
Solubility :	0.271 mg/ml ; 0.000982 mol/l
Class :	Soluble
Log S (Ali) :	-3.0
Solubility :	0.278 mg/ml ; 0.00101 mol/l
Class :	Soluble
Log S (SILICOS-IT) :	-3.97
Solubility :	0.0298 mg/ml ; 0.000108 mol/l
Class :	Soluble

Medicinal Chemistry

PAINS :	0.0 alert
Brenk :	0.0 alert
Leadlikeness :	0.0
Synthetic accessibility :	2.83

Safety of [ 502649-29-8 ]

Signal Word:	Warning	Class:	N/A
Precautionary Statements:	P261-P305+P351+P338	UN#:	N/A
Hazard Statements:	H302-H315-H319-H335	Packing Group:	N/A
GHS Pictogram:

Application In Synthesis of [ 502649-29-8 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

Upstream synthesis route of [ 502649-29-8 ]
Downstream synthetic route of [ 502649-29-8 ]

[ 502649-29-8 ] Synthesis Path-Upstream 1~6

1
[ 847554-73-8 ]
[ 502649-29-8 ]

Reference： [1] Tetrahedron, 2007, vol. 63, # 14, p. 3057 - 3065

2
[ 63-91-2 ]
[ 502649-29-8 ]

Reference： [1] Patent: US2003/153556, 2003, A1,

3
[ 24424-99-5 ]
[ 502649-29-8 ]

Reference： [1] Tetrahedron, 2007, vol. 63, # 14, p. 3057 - 3065

4
[ 216228-85-2 ]
[ 502649-29-8 ]

Reference： [1] Tetrahedron, 2007, vol. 63, # 14, p. 3057 - 3065

5
[ 143540-05-0 ]
[ 502649-29-8 ]

Reference： [1] Tetrahedron, 2007, vol. 63, # 14, p. 3057 - 3065

6
[ 181955-79-3 ]
[ 502649-29-8 ]

Reference： [1] Tetrahedron, 2007, vol. 63, # 14, p. 3057 - 3065

[ 502649-29-8 ] Synthesis Path-Downstream 1~39

1
[ 501-53-1 ]
[ 502649-29-8 ]
1-benzyl-4-(tert-butyl)-2-benzylpiperazine-1,4-dicarboxylate [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
268 mg	With triethylamine; In dichloromethane; at 20℃; for 2h;Cooling with ice;	To a flask was added tert- butyl 3-benzylpiperazine-1-carboxylate (CAS: 502649-29-8, Vendor: BePharm, 300 mg, 1.09 mmol), TEA (330 mg, 454 pL, 3.26 mmol) and DCM (2 mL). Then it was cooled with ice bath and Cbz-Cl (278 mg, 232 pL, 1.63 mmol) was added drop-wise. After being warmed to rt slowly and stirred for 2 hrs, the reaction mixture was diluted with 20 mL water and extracted with EA (15 mL) twice, the organic layer was dried over Na2S04 and concentrated to give a brown oil. After purification by flash column (EA/PE= 0 to 20%), the compound 39a (268 mg) was obtained as an oil. MS: calc'd 411 (MH+), measured 411 (MH+).
368 mg	With triethylamine; In dichloromethane; at 20℃; for 2h;	To a solution of <strong>[502649-29-8]tert-butyl 3-benzylpiperazine-1-carboxylate</strong> (300 mg, 1.09 mmol) in DCM (10 mL) was added TEA (330 mg, 0.45 mL, 3.26 mmol) and CbzCl (278 mg, 0.23 mL, 1.63 mmol). After the reaction mixture was then stirred at rt for 2 hrs. The mixture was diluted with water, and extracted with EtOAc. The organic layer was washed with brine, dried over Na2SO4 and concentrated to give crude product which was purified by column chromatography to give a product (368 mg) as an oil. The oil was dissolved in DCM (2 mL), then TFA (124 mg, 84 muL, 1.09 mmol) was added. The reaction mixture was stirred at rt overnight, then concentrated to give a crude compound 77a (385 mg) as an oil which is directly used in next step. MS: calc?d 311 (MH+), measured 311 (MH+).

Reference： [1]Organic Letters,2016,vol. 18,p. 1732 - 1735
[2]Bioorganic and Medicinal Chemistry Letters,2004,vol. 14,p. 4763 - 4766
[3]Patent: WO2019/238629,2019,A1 .Location in patent: Page/Page column 54
[4]Patent: WO2020/52738,2020,A1 .Location in patent: Page/Page column 70-71

2
[ 847554-73-8 ]
[ 502649-29-8 ]

Reference： [1]Tetrahedron,2007,vol. 63,p. 3057 - 3065

3
[ 331432-91-8 ]
[ 502649-29-8 ]
[ 1007352-17-1 ]

Yield	Reaction Conditions	Operation in experiment
74%	With sodium t-butanolate;palladium diacetate; tri-tert-butyl phosphine; In xylene; at 80℃; for 0.666667h;	To a mixture of Pd(OAc)2 (0.054 g, 0.2 mmol), NaOtBu (0.64 g, 6.6 mmol) in xylene (7.0 mL) in a screw-capped tube was added tBu3P (0.049 g, 0.2 mmol). After 10 minutes a solution of 5-bromo-1-(tert-butyl-dimethyl-silanyl)-1H-indole (1.30 g, 4.4 mmol) in xylene (7.0 mL) and a solution of <strong>[502649-29-8]3-benzyl-piperazine-1-carboxylic acid tert-butyl ester</strong> (1.34 g, 4.8 mmol) in xylene (8.0 mL) were added. The mixture was heated to 80 C. for 30 minutes, then cooled to room temperature. The reaction mixture was taken up in ethyl acetate, filtered through a pad of celite, and concentrated under reduced pressure. Purification via flash chromatography (gradient: 2% to 20% EtOAc in hexane) afforded 3-Benzyl-4-[1-(tert-butyl-dimethyl-silanyl)-1H-indol-5-yl]-piperazine-1-carboxylic acid tert-butyl ester (1.65 g, 74%) as a pale yellow solid; MS (M+H)=506.

Reference： [1]Bioorganic and Medicinal Chemistry Letters,2010,vol. 20,p. 3941 - 3945
[2]Patent: US2008/45543,2008,A1 .Location in patent: Page/Page column 24-25

4
2-(hydroxy-phenyl-methyl)-piperazine-1,4-dicarboxylic acid di-tert-butyl ester [ No CAS ]
[ 502649-29-8 ]

Reference： [1]Tetrahedron,2007,vol. 63,p. 3057 - 3065

5
[ 24424-99-5 ]
[ 502649-29-8 ]

Reference： [1]Tetrahedron,2007,vol. 63,p. 3057 - 3065

6
[ 216228-85-2 ]
[ 502649-29-8 ]

Reference： [1]Tetrahedron,2007,vol. 63,p. 3057 - 3065

7
[ 143540-05-0 ]
[ 502649-29-8 ]

Reference： [1]Tetrahedron,2007,vol. 63,p. 3057 - 3065

8
[ 181955-79-3 ]
[ 502649-29-8 ]

Reference： [1]Tetrahedron,2007,vol. 63,p. 3057 - 3065

9
[ 502649-29-8 ]
[ 481038-64-6 ]

Reference： [1]Bioorganic and Medicinal Chemistry Letters,2004,vol. 14,p. 4763 - 4766
[2]Patent: WO2019/238629,2019,A1
[3]Patent: WO2020/52738,2020,A1

10
[ 502649-29-8 ]
[ 481038-65-7 ]